As Abiomed (ABMD) Market Valuation Rose, Biondo Investment Advisors Upped Position by $609,620; As Anheuser Busch Inbev Sa/Nv (BUD) Market Valuation Declined, Commerce Bank Lifted by $536,130 Its Stake

April 25, 2018 - By Maria Brooks

ABIOMED, Inc. (NASDAQ:ABMD) Logo

Biondo Investment Advisors Llc increased its stake in Abiomed Inc (ABMD) by 4.9% based on its latest 2017Q4 regulatory filing with the SEC. Biondo Investment Advisors Llc bought 3,260 shares as the company’s stock rose 49.46% while stock markets declined. The institutional investor held 69,794 shares of the health care company at the end of 2017Q4, valued at $13.08 million, up from 66,534 at the end of the previous reported quarter. Biondo Investment Advisors Llc who had been investing in Abiomed Inc for a number of months, seems to be bullish on the $12.92B market cap company. The stock increased 0.32% or $0.93 during the last trading session, reaching $291.86. About 686,252 shares traded or 51.98% up from the average. ABIOMED, Inc. (NASDAQ:ABMD) has risen 128.67% since April 25, 2017 and is uptrending. It has outperformed by 117.12% the S&P500.

Commerce Bank increased its stake in Anheuser Busch Inbev Sa/Nv (BUD) by 33.87% based on its latest 2017Q4 regulatory filing with the SEC. Commerce Bank bought 4,830 shares as the company’s stock declined 3.67% with the market. The institutional investor held 19,092 shares of the beverages (production and distribution) company at the end of 2017Q4, valued at $2.13 million, up from 14,262 at the end of the previous reported quarter. Commerce Bank who had been investing in Anheuser Busch Inbev Sa/Nv for a number of months, seems to be bullish on the $201.83B market cap company. The stock increased 0.32% or $0.33 during the last trading session, reaching $102.81. About 1.31 million shares traded. Anheuser-Busch InBev SA/NV (NYSE:BUD) has declined 3.50% since April 25, 2017 and is downtrending. It has underperformed by 15.05% the S&P500.

Investors sentiment decreased to 0.96 in Q4 2017. Its down 0.31, from 1.27 in 2017Q3. It dived, as 44 investors sold BUD shares while 158 reduced holdings. 56 funds opened positions while 138 raised stakes. 94.11 million shares or 1.92% more from 92.33 million shares in 2017Q3 were reported. Jane Street Gp Ltd invested 0.03% in Anheuser-Busch InBev SA/NV (NYSE:BUD). Blair William & Communication Il invested in 0.11% or 146,700 shares. Rathbone Brothers Public Ltd Com holds 0.03% of its portfolio in Anheuser-Busch InBev SA/NV (NYSE:BUD) for 6,502 shares. Signature Mngmt Inc accumulated 2,850 shares or 0.09% of the stock. Farmers And Merchants Invs Incorporated, a Nebraska-based fund reported 54 shares. Godshalk Welsh Capital Mngmt holds 0.32% in Anheuser-Busch InBev SA/NV (NYSE:BUD) or 2,800 shares. 64,664 were accumulated by Patriot Wealth. Sterling Cap Ltd has 0.01% invested in Anheuser-Busch InBev SA/NV (NYSE:BUD). Guardian Cap LP has invested 0.46% of its portfolio in Anheuser-Busch InBev SA/NV (NYSE:BUD). Raymond James Advsr holds 0.03% or 46,367 shares in its portfolio. Pictet & Cie (Europe) Sa reported 3,500 shares or 0.06% of all its holdings. Clearbridge Limited Liability Company has invested 0% in Anheuser-Busch InBev SA/NV (NYSE:BUD). Grantham Mayo Van Otterloo & Com Ltd Liability Corporation invested in 0.15% or 222,600 shares. Allen Invest Mgmt Lc stated it has 3.74% in Anheuser-Busch InBev SA/NV (NYSE:BUD). Ironwood Invest Counsel Llc has invested 1.08% of its portfolio in Anheuser-Busch InBev SA/NV (NYSE:BUD).

Among 23 analysts covering Anheuser-Busch InBev (NYSE:BUD), 16 have Buy rating, 2 Sell and 5 Hold. Therefore 70% are positive. Anheuser-Busch InBev had 50 analyst reports since July 21, 2015 according to SRatingsIntel. The firm earned “Outperform” rating on Friday, November 25 by Macquarie Research. The rating was upgraded by Credit Agricole to “Outperform” on Monday, November 2. The rating was reinitiated by JP Morgan with “Neutral” on Tuesday, October 11. Bernstein upgraded the shares of BUD in report on Monday, March 12 to “Outperform” rating. UBS initiated Anheuser-Busch InBev SA/NV (NYSE:BUD) on Wednesday, September 30 with “Buy” rating. The firm earned “Buy” rating on Tuesday, June 27 by Jefferies. The firm earned “Buy” rating on Friday, July 28 by Jefferies. The company was upgraded on Monday, August 22 by Kepler Cheuvreux. Sterne Agee CRT initiated the stock with “Buy” rating in Tuesday, July 21 report. JP Morgan maintained the stock with “Underweight” rating in Thursday, February 15 report.

Commerce Bank, which manages about $7.68 billion US Long portfolio, decreased its stake in Abb Ltd (NYSE:ABB) by 61,577 shares to 74,979 shares, valued at $2.01M in 2017Q4, according to the filing. It also reduced its holding in Energizer Hldgs Inc New by 9,298 shares in the quarter, leaving it with 260,723 shares, and cut its stake in Tjx Cos Inc New (NYSE:TJX).

Investors sentiment decreased to 1.18 in 2017 Q4. Its down 0.12, from 1.3 in 2017Q3. It dropped, as 19 investors sold ABMD shares while 110 reduced holdings. 55 funds opened positions while 97 raised stakes. 36.44 million shares or 5.39% less from 38.51 million shares in 2017Q3 were reported. Duncker Streett & has 175 shares for 0.01% of their portfolio. Pnc Serv Gp holds 9,814 shares or 0% of its portfolio. Texas Permanent School Fund owns 0.07% invested in ABIOMED, Inc. (NASDAQ:ABMD) for 28,394 shares. Advisor Limited Liability Com accumulated 915 shares. Hanseatic Service stated it has 3,074 shares. Sumitomo Mitsui Asset Mngmt invested in 21,388 shares. New York State Common Retirement Fund reported 0.07% stake. Metropolitan Life Insurance New York reported 13,884 shares. Amp Cap Investors Ltd has invested 0.02% in ABIOMED, Inc. (NASDAQ:ABMD). Raymond James And Associate holds 0.01% or 19,607 shares. Teacher Retirement Systems Of Texas owns 14,424 shares. Perceptive Advisors Limited Liability invested in 1.34% or 215,000 shares. New Mexico Educational Retirement Board invested in 10,400 shares or 0.07% of the stock. Bbva Compass Commercial Bank Inc has invested 0.02% in ABIOMED, Inc. (NASDAQ:ABMD). Regions Corp has 70 shares.

Since February 20, 2018, it had 0 buys, and 1 sale for $5.41 million activity.

Among 15 analysts covering Abiomed (NASDAQ:ABMD), 12 have Buy rating, 0 Sell and 3 Hold. Therefore 80% are positive. Abiomed had 35 analyst reports since August 4, 2015 according to SRatingsIntel. The firm has “Buy” rating by Jefferies given on Thursday, September 21. The rating was initiated by SunTrust on Friday, September 29 with “Buy”. Jefferies maintained the shares of ABMD in report on Thursday, August 3 with “Buy” rating. The stock of ABIOMED, Inc. (NASDAQ:ABMD) has “Buy” rating given on Wednesday, December 7 by Guggenheim. Piper Jaffray maintained ABIOMED, Inc. (NASDAQ:ABMD) rating on Thursday, January 4. Piper Jaffray has “Buy” rating and $220.0 target. The stock of ABIOMED, Inc. (NASDAQ:ABMD) has “Buy” rating given on Thursday, February 1 by Piper Jaffray. The stock has “Buy” rating by William Blair on Thursday, June 8. The rating was maintained by BTIG Research with “Hold” on Tuesday, August 4. Stephens maintained ABIOMED, Inc. (NASDAQ:ABMD) rating on Friday, February 2. Stephens has “Buy” rating and $274.0 target. The firm has “Hold” rating given on Wednesday, August 5 by Piper Jaffray.

ABIOMED, Inc. (NASDAQ:ABMD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts